Esperion Therapeutics, Inc. — Director's Dealing 2021

Jun 30, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Esperion Therapeutics, Inc. (ESPR)
CIK: 0001434868
Period of Report: 2021-06-28

Reporting Person: Bartram Richard (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-28	Stock Option (right to buy)	$22.52	A	37500	Acquired	2031-06-28	Common Stock (37500.0)	Direct
2021-06-28	Performance-based Restricted Stock Units	$	A	26400	Acquired	2023-06-30	Common Stock (26400.0)	Direct

Footnotes

F1: Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be October 15, 2021.

F2: Each Performance-Based Restricted Stock Unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock.

F3: These shares were issued in connection with a reward of performance-based restricted stock units that will vest only if performance goals are achieved over a two-year period beginning July 1, 2021. The actual number of units (if any) received under this award will depend on continued employment and actual performance over the two-year performance period.